Comparison
While LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215, PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101.
While LL-37 works as a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586, PT-141 is the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101.
LL-37 is 37 amino acids long, whereas PT-141 is shorter as it has a length of 7 amino acids. LL-37 is made up of a sequence of Leucine, Leucine, Glycine, Aspartic acid, Phenylalanine, Phenylalanine, Arginine, Lysine, Serine, Lysine, Glutamic acid, Lysine, Isoleucine, Glycine, Lysine, Glutamic acid, Phenylalanine, Lysine, Arginine, Isoleucine, Valine, Glutamine, Arginine, Isoleucine, Lysine, Aspartic acid, Phenylalanine, Leucine, Arginine, Asparagine, Leucine, Valine, Proline, Arginine, Threonine, Glutamic acid, Serine. PT-141 is made up of a sequence of sequence data not available in the current dataset.
LL-37
CAMP
PT-141
POMC
No related articles are linked to these peptides yet.